Dose-response of inhaled drugs in asthma. An update

Clinical Pharmacokinetics

Volumn 32, Issue 1, 1997, Pages 58-74

  Clark, David J ^a   Lipworth, Brian J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FENOTEROL; FLUTICASONE; FORMOTEROL; HYDROCORTISONE; SALBUTAMOL; SALMETEROL;

ASTHMA; BONE METABOLISM; BRONCHODILATATION; CARDIOTOXICITY; CLINICAL PRACTICE; CLINICAL TRIAL; DEMOGRAPHY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPERGLYCEMIA; HYPOKALEMIA; INHALATIONAL DRUG ADMINISTRATION; INHALER; LIPOPHILICITY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; TACHYPHYLAXIS; TREMOR;

EID: 0031027706     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199732010-00003     Document Type: Review

References (78)

1. Jack D. A way of looking at agonism and antagonism: lessons from salbutumol, salmeterol and other β-adrenoceptor agonists. Br J Clin Pharmacol 1991; 31: 501-14
2. Jeppsson AB, Lofdahl CG, Waldeck B, et al. On the predictive value of experiments in vitro in the evaluation of the effect duration of bronchodilator drugs for local administration. Pulmon Pharmacol 1989; 2: 81-5
3. 2-adrenoceptor partial agonist/antagonist activity of salbutamol in states of low and high adrenergic tone. Thorax 1995; 50: 134-8
4. 2-adrenoceptor agonist/antagonist activity of formoterol and salmeterol. Thorax 1996; 51: 54-8
5. 2-adrenoceptor agonist bronchodilator. Life Sci 1993; 52: 2145-60
6. Linden A, Bergendal A, Ullman A, et al. Salmeterol, formoterol and salbutamol in the isolated guinea pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism. Thorax 1993; 48: 547-53
7. Advenier C, Zhang Y, Naline E, et al. Effects of formoterol on isolated human bronchus [abstract]. Am Rev Respir Dis 1991; 143: A651
8. 2 adrenoceptor agonists with higher efficacy on guinea-pig trachea and human bronchus in vitro. Br J Pharmacol 1994; 113: 687-92
9. Windom H, Burgess C, Siebers R, et al. The pulmonary and extra-pulmonary effects of inhaled β-agonists in patients with asthma. Clin Pharmacol Ther 1990; 48: 296-301
10. Wong CS, Pavord ID, Williams J, et al. Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet 1990; 336: 1396-9
11. Newhouse MT, Dolovich MB, Kazim F. Dose-effect relationship of the β-agonists fenoterol and salbutamol in patients with asthma. Chest 1994; 105: 1738-42
12. Lipworth BJ, Newhnam DM, Clark RA, et al. Comparison of the relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients. Thorax 1995; 50: 54-61
13. Lipworth BJ, Clark RA, Dhillon DP, et al. Beta-adrenoceptor responsiveness to inhaled salbutamol in patients with bronchial asthma. Br J Clin Pharmacol 1988; 26: 527-33
14. Lipworth BJ, McDevitt DG. Beta-adrenoceptor responses to inhaled salbutamol in normal subjects. Eur J Clin Pharmacol 1989; 36: 239-45
15. Bremner P, Burgess C, Beasley R, et al. Nebulised fenoterol causes greater cardiovascular and hypokalaemic effects than equivalent bronchodilator doses of salbutamol in asthmatics. Respir Med 1992; 86: 419-23
16. 2 activity of inhaled fenoterol and salbutamol in normal subjects. Thorax 1993; 48: 656-8
17. 2-agonists fenoterol and salbutamol on force of contraction in isolated human ventricular myocardium. Klin Wochenschr 1985; 63: 26-7
18. Wilson C, Lincoln C. β-Adrenoceptor subtypes in human, rat, guinea-pig and rabbit atria. J Cardiovasc Pharmacol 1984; 5: 1216-21
19. O'Donnell SR, Wanstall JC. Evidence that the efficacy (intrinsic activity) of fenoterol is higher than that of salbutamol on β-adrenoceptors on guinea-pig trachea. Eur J Pharmacol 1978; 47: 333-40
20. Lipworth BJ, Struthers AD, McDevitt DG, et al. Tachyphylaxis to systemic but not airways responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. Am Rev Respir Dis 1989; 140: 586-92
21. Smyth ET, Pavord ID, Wong CS, et al. Interaction and dose equivalence of salbuterol and salmeterol in patients with asthma. BMJ 1993; 306: 543-545
22. 2-responses to fenoterol. Thorax 1996; 51: 585-9
23. Dahl R, Earnshaw JS, Palmer JBD. Salmeterol: a 4 week study of long-acling beta-adrenoceptor agonist for the treatment of reversible airways disease. Eur Respir J 1991; 4: 1178-84
24. Faurschou P. Chronic dose-ranging studies with salmeterol. Eur Respir Rev 1991; 1 (4): 282-7
25. Rabe KF, Jorres R, Nowak D, et al. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. Am Rev Respir Dis 1993; 147: 1436-41
26. Bronsky E, Kemp J, Orgel H, et al. A 1-week dose ranging study of inhaled salmeterol in patients with asthma. Chest 1994; 105: 1032-37
27. Bennett JA, Smyth ET, Pavord ID, et al. Systemic effects of salbutamol and salmeterol in patients with asthma. Thorax 1994; 49: 771-4
28. Bennett JA, Tattersfield AE. Dose equivalence of systemic effects from non-cumulative doses of salmeterol and salbutamol in healthy subjects [abstract]. Thorax 1995; 50 Suppl. 2: A77
29. Johnson MA, Newman SP, Bloom R, et al. Delivery of albuterol and ipratropium bromide from two nebuliser systems in chronic stable asthma. Chest 1989; 96: 1-10
30. Newnham DM, Lipworth BJ. Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system ('Venstream'). Thorax 1994; 49: 762-70
31. Ekstrom T, Andersson AC, Skedinger M, et al. Dose potency relationship of terbutaline inhaled via Turbohaler or via pressurised metered dose inhaler. Ann Allergy Asthma Immunol 1995; 74: 328-32
32. Borgstom L, Derom E, Stahl E, et al. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med 1996; 153: 1636-40
33. Lofdahl CG, Andersson L, Carlsson LG, et al. Lower nominal dose required of inhaled salbutamol via turbuhaler compared with pressurised metered dose inhaler, for the same bronchodilating effect. Am J Respir Crit Care Med 1994; 149: A219
34. Carlsson LG, Arwestrom E, Friberg K, et al. Half the dose of salbutamol required by turbuhaler compared with diskhaler for the same bronchodilating effect. Eur Respir J 1995; 8 Suppl. 19: 201
35. Tonnesen F, Laursen LC, Evald T, et al. Bronchodilating effect of terbutaline powder in acute severe bronchial obstruction. Chest 1994; 105: 697-700
36. Toogood JH, Baskerville J, Jennings B, et al. Bioequivalent doses of budesonide and prednisone in moderate and severe asthma. J Allergy Clin Immunol 1989; 84: 668-70
37. English AF, Neate MS, Quint DJ, et al. Biological activities of some corticosteroids used in asthma [abstract]. Am J Respir Crit Care Med 1994; 149 Suppl.: A212
38. Anderson N, Klint S, Randwall G, et al. Equipotency of budesonide and fluticasone propionate in the vasoconstriction assay [abstract]. Thorax 1994; 49: 422P
39. Phillips GH. Structure-activity relationships of topically active stertoids: the selection of fluticasone propionate. Respir Med 1990; 84 Suppl. A: 19-23
40. Martine LE, Harrison C, Tanner RJN. Metabolism of beclomethasone dipropionate by animals and man. Postgrad Med J 1975; 51 Suppl. 4: 11-20
41. Ryrfeldt A, Andersson P, Edsbacker S, et al. Pharmacokinetics and metabolism of budesonide: a selective glucocorticoid. Eur J Respir Dis 1982; 63 Suppl. 122: 86-95
42. Harding SM. The human pharmacology of fluticasone propionate. Respir Med 1990; 84 Suppl. A: 25-9
43. Toogood JH, Lefcoe NM, Haines DSM, et al. A graded dose assessment of the efficacy of beclomethasone dipropionate aerosol for severe chronic asthma. J Allergy Clin Immunol 1977; 59: 248-308
44. Smith MJ, Hodson ME. High dose beclomethasone inhaler in the treatment of asthma. Lancet 1983; I: 265-9
45. Dahl R, Lundback B, Malo J, et al. A dose-ranging study of fluticasone propionate in adults with moderate asthma. Chest 1993; 104: 1352-8
46. Lipworth BJ. Clinical pharmacology of corticosteroids in bronchial asthma. Pharmacol Ther 1993; 58: 173-209
47. Lundback B, Alexander M, Day J, et al. Evaluation of fluticasone propionate (500μg day) administered either as dry powder via a Diskhaler inhaler or pressurized inhaler and compared with beclomethasone dipropionate (1000μg day) administered by pressurized inhaler. Respir Med 1993; 87: 609-20
48. Barnes NC, Marone G, DiMaria GU, et al. A comparison of fluticasone propionate, 1mg daily, with beclomethasone dipropionate, 2mg daily, in the treatment of severe asthma. Eur Respir J 1993; 6: 877-84
49. Fabbri L, Burge PS, Croonenborgh L, et al. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. Thorax 1993; 48: 817-23
50. Boe J, Bakke P, Rodolen T, et al. High-dose inhaled steroids in asthmatics: moderate efficacy gain and suppression of hypothalamic-pituitary-adrenal (HPA) axis. Eur Respir J 1994; 7: 2179-84
51. Leblanc P, Mink S, Keistinen T, et al. A comparison of fluticasone propionate 200 μg/day with beclomethasone dipropionate 400 μg/day in adult asthma. Allergy 1994; 49: 380-5
52. Ayres JG, Bateman ED, Lundback B, et al. High dose fluticasone propionate, 1mg daily, versus fluticasone propionate, 2mg daily, or budesonide, 1.6mg daily, in patients with chronic severe asthma. Eur Respir J 1995; 8: 579-86
53. Bootsma GP, Dekhuijzen PNR, Festen J, et al. Comparison of fluticasone propionate and beclomethasone dipropionate on direct and indirect measurements of bronchial hyperresponsiveness in patients with stable asthma. Thorax 1995; 50: 1044-50
54. Gustafsson P, Tsanakas J, Gold M, et al. Comparison of the efficacy and safety of inhaled fluticasone propionate 200 μg/day with inhaled beclomethasone 400 μg/day in mild and moderate asthma. Arch Dis Child 1993; 69: 206-11
55. Selroos O, Backman R, Forsen K, et al. Clinical efficacy of budesonide turbohaler compared with that of beclomethasone dipropionate PMDI with volumatic spacer. Allergy 1994; 49: 833-6
56. Agertoft L, Pederson S. Importance of the inhalation device on the effect of budesonide. Arch Dis Child 1993; 69: 130-3
57. Honor JW. Hypothalamic pituitary adrenal axis. Respir Med 1994; 88 Suppl. A: 9-15
58. Brown PH, Blundell G, Greening AP, et al. Screening for hypothalamo-pituitary-adrenal axis suppression in asthmatics inhaling high dose corticosteroids. Respir Med 1991; 85: 511-6
59. McIntyre HD, Mitchell CA, Bowler SD, et al. Measuring the systemic effects of inhaled beclomethasone: timed morning urine collections compared with 24 hour specimens. Thorax 1995; 50: 1280-4
60. Schlaghecke R, Kornely E, Santen RT, et al. The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med 1992; 326: 226-30
61. Brown PH, Blundell G, Greening AP, et al. High dose inhaled corticosteroid and the corticoid stress response to acute severe asthma. Respir Med 1992; 86: 495-27
62. Grahnen A, Eckernas SA, Brundin RM, et al. An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. Br J Clin Pharmacol 1994; 38: 521-5
63. Lonnebro A, Grahnen A, Jansson B, et al. An assessment of the systemic effects of single and repeated doses of inhaled fluticasone propionate and inhaled budesonide in healthy volunteers. Eur J Clin Pharmacol 1996; 49: 459-63
64. Grove A, Allam C, McFarlane L, et al. A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects. Br J Clin Pharmacol 1994; 38: 527-32
65. Boorsma M, Andersson N, Larsson P, et al. Assessment of the realtive systemic potency of inhaled fluticasone and budesonide. Eur Respir J 1996; 9: 1427-14
66. Clark DJ, Grove A, Cargill RI, et al. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 1996; 51: 262-6
67. Clark DJ, Lipworth BJ. Adrenal suppression with chronic dosing with fluticasone propionate compared with budesonide in adult asthmatic patients. Thorax. In press
68. Clark DJ, Clark RA, Lipworth BJ. Adrenal suppression with inhaled budesonide and fluticasone propionate given by large volume spacer in asthmatic children. Thorax 1996; 51: 941-3
69. Pedersen S, Steffensen G, Eknas I, et al. Pharmacokinetics of budesonide in children with asthma. Eur J Clin Pharmacol 1987; 31: 579-82
70. Thorsson L, Dahlstrom K, Edsbacker S, et al. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol. In press.
71. Thorrson L, Edsbacker S, Conradson TB. Lung deposition of budesonide from Turbuhaler is twice that from pressurised metered-dose inhaler. Eur Respir J 1994; 71: 1839-44
72. Wurthwein G, Rehder S, Rohdewald P. Lipophilicity and receptor affinity of glucocorticosteroids. Pharm Ztg Wiss 1992; 4: 161-7
73. Brown PH, Matusiewicz SP, Shearing C, et al. Systemic effects of high dose inhaled steroids: comparison of beclomethasone dipropionate and budesonide in healthy subjects. Thorax 1993; 48: 967-73
74. Toogood J, Baskerville J, Jennings B, et al. Use of spacers to facilitate inhaled corticosteroid treatment of asthma. Am Rev Respir Dis 1984; 129: 723-9
75. Kerstjens HU, Postma DS, Doormaal JJ, et al. Effects of short term and long term treatment with inhaled corticosteroids on bone metabolism in patients with airways obstruction. Thorax 1994; 49: 652-6
76. Grove A, McFarlane LC, Jackson CM, et al. Effects of short term exposure to high dose inhaled corticosteroids on novel markers of bone metabolism. Eur J Clin Pharmacol 1996; 50: 275-277
77. Jennings BH, Andersson KE, Johannsson SA. Assessment of systemic effects of inhaled glucocorticosteroids: comparison of the effects of inhaled budesonide and oral prednisolone on adrenal function and markers of bone turnover. Eur J Clin Pharmacol 1991; 40: 77-82
78. 2-adrenoceptor function in asthmatic patients. Chest 1996; 109: 343-7